<DOC>
	<DOCNO>NCT01277549</DOCNO>
	<brief_summary>The purpose protocol characterize performance CaridianBCT 's Spectra Optia Apheresis System , use collect mononuclear cell ( MNCs ) cluster differentiation 34 ( CD34 ) positive cell healthy nonmobilized blood donor healthy G-CSF ( granulocyte colony stimulate factor ) mobilize blood donor , respectively .</brief_summary>
	<brief_title>Evaluation Spectra Optia® Apheresis System Mononuclear Cell ( MNC ) Collection Procedure Healthy Blood Donors</brief_title>
	<detailed_description />
	<criteria>Acceptable health history allow blood product collection Weight &gt; 50 &lt; 125 Kg ( kilogram ) . Male nonpregnant , nonnursing female . General good health , determine questionnaire . Normal prescreening complete blood count . Platelet count &gt; 150 x 10^3/uL ( microliter ) initial screen &gt; 120 x 10^3/uL immediately prior leukapheresis . Adequate peripheral venous access allow collection product . Able read , understand , sign inform consent form . Additional Inclusion Criteria Mobilized Subjects If male , willing use condom sexual relation female partner 48 hour follow last GCSF injection . If female childbearing potential , willing use medically acceptable contraceptive 48 hour follow last GCSF injection . ) Collection loss : ½ pint ( 1 cup ) whole blood within prior 56 day , 3 L ( liter ) whole blood 1.5 L red blood cell within prior 12 month , 12 L plasma within prior 12 month , leukapheresis within prior six week , plateletpheresis within prior 48 hour two within prior 7 day twentyfour within last 12 month , plasmapheresis within prior 48 hour two within prior 7 day . Acute symptomatic chronic lung disease . Active chronic heart disease , include hypertension control medication . History hematologic malignancy chronic hematologic disorder bleed disorder . Reactive test indicative infection T. pallidum , Human Tlymphotropic virus , HIV , Hepatitis C Virus , Hepatitis B Virus ( except isolate Hepatitis B Core Antibody Reactivity . Presence psychological trait physiological medical condition would make subject unlikely tolerate procedure . Subjects take prescription medication deem allowable investigator . Abnormal serum electrolytes serum calcium level . Abnormal serum creatinine level . Abnormal liver function result ALT ( alanine amino transferase ) test . Abnormal coagulation test prothrombin time partial thromboplastin time . Inadequate antecubital vein leukapheresis inability unwillingness tolerate leukapheresis . If female , pregnant lactating . Additional Exclusion Criteria Mobilized Subjects Received GCSF injection prior 4 month , receive twentyfive ( 25 ) dos GCSF ( dose include several individual injection administer one occasion ) . Known hypersensitivity GCSF E. coliderived product . History autoimmune condition disorder , unless approve principal investigator . Immediate family history ( parent , grandparent , sibling , child ) hematologic malignancy . Active history iritis ( anterior uveitis ) episcleritis . History deep vein thrombosis pulmonary embolism . Current treatment lithium . Spleen tip palpable physical exam . Positive SickleDex test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Leukapheresis</keyword>
	<keyword>Hematopoetic Stem Cell Mobilization</keyword>
</DOC>